TABLE 1.
Method | Wallace et al. (1993) | Melder et al. (2002) | Present Study | |||
---|---|---|---|---|---|---|
Labeling | I-125 PKH95–labeled T cells | In-111 oxine–labeled T cells | Cr-51–labeled T cells | |||
Preparation of T cells | Splenocytes exposed to 6000 IU/ml IL-2 | TILs extracted from MC38 s.c. tumors | Lymphocytes extracted from spleen | Mice sensitized with splenocytes of MCaIV tumor-bearing C3H mice and lymphocytes extracted from spleen | Splenocytes expanded using anti-CD3, anti-CD28, and IL-2 | TILs extracted from B16-BL6 s.c. tumors |
Tissues listed in descending order of concentrations at 20–24 h | Spleen | Lung | Spleen | Lung | Spleen | Lung |
Lung | Spleen | Liver | Spleen | Liver | Spleen | |
Liver | Liver | Lung | Liver | Lung | Liver | |
Skin | Skin | Tumor | Tumor | Kidney | Kidney | |
Muscle | Muscle | Heart | Heart | TDLN | Tumor |